Is Nurexone Biologic Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Nurexone Biologic Inc (NRX.V) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nurexone Biologic Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nurexone Biologic Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Nurexone Biologic Inc?

Muslim investors may consider investing in Nurexone Biologic Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nurexone Biologic Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Nurexone Biologic Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nurexone Biologic Inc updated?

The Shariah compliance status of Nurexone Biologic Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nurexone Biologic Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nurexone Biologic Inc?

You can check the latest Shariah compliance status of Nurexone Biologic Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NRX.V Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 09, 2025

Report Source: 2025 1st Quarter Report

Analyst's Ratings for Nurexone Biologic Inc (NRX.V)

Based on 9 analysts giving stock ratings to Nurexone Biologic Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Nurexone Biologic Inc. Stock Analysis NRX.V

Canada Health Care Nano Cap Report: Q1, 2025

NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The company is headquartered in Haifa, Haifa. The company went IPO on 2012-05-08. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.

Key Statistics of Nurexone Biologic Inc (NRX.V)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

CAD0.66CAD0.66

Today's Open

CAD0.66

Volume

1569.00

P/E Ratio (TTM)

52 Week Range

CAD0.54CAD1.14

Market Cap

40.37M

Avg. Volume

22.63K

Dividend Yield

Financial Metrics & Statements of Nurexone Biologic Inc (NRX.V)

FAQ's for Nurexone Biologic Inc (NRX.V)

According to Musaffa’s Shariah screening methodology, Nurexone Biologic Inc (NRX.V) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.